Preliminary Program: Sunday, May 20
8 a.m.-Noon
CME Courses 14-19
8 a.m.-11 a.m.
Industry-Supported Symposia
IS8. The Ongoing Debate Surrounding Atypicals: Are the Benefits Worth the Risks? Supported by Solvay Pharmaceuticals and Wyeth Pharmaceuticals
Balancing Between Efficacy and Side Effects Samuel J. Keith, M.D.
The Ongoing Debate Surrounding Atypicals: Do the Benefits Outweigh the Risks? Henry A. Nasrallah, M.D.
The Risk/Benefit Ratio of Atypical Antipsychotics in Early Phase Schizophrenia Elizabeth Bromley, M.D.
New Mechanisms and Pharmacological Strategies Stephen R. Marder, M.D.
IS9. Still Sleepy After All These Cures: Hypersomnia in Psychiatry Supported by Cephalon Inc.
The Neurobiology of Hypersomnia Stephen M. Stahl, M.D., Ph.D.
The Clinical Spectrum of Hypersomnia Daniel J. Buysse, M.D.
Measurement of Hypersomnia Meeta Singh, M.D.
Strategies for the Management of Hypersomnia Leslie P. Lundt, M.D.
Prevalence and Consequences of Hypersomnia Christoper L. Drake, Ph.D.
IS10. Deconstructing Attention and Cognition in ADHD: New Understandings for Improved Management Supported by McNeil Pediatrics
Overview of ADHD Thomas J. Spencer, M.D.
Neurocircuitry in ADHD Francisco Xavier Castellanos, M.D.
Pharmacological Treatment of ADHD: Focus on Attention Timothy E. Wilens, M.D.
Neuropsychology in ADHD Larry J. Seidman, Ph.D.
Understanding Cognitive and Behavioral Approaches to Treating ADHD in Adults Steven A. Safren, Ph.D.
IS11. Long-Term Treatment Approaches for Schizophrenia: Comparing Maintenance and Recovery Models Supported by Bristol-Myers Squibb Co.
Maintenance and Recovery in Schizophrenia Stephen R. Marder, M.D.
To Be Announced Peter F. Buckley, M.D.
To Be Announced Peter Weiden, M.D.
Adherence With Pharmacotherapy in Schizophrenia and Cognitive-Behavior Therapy Shanaya Rathod, M.D.
IS12. Dark Horizons: Depression and Cognitive Impairment Supported by Forest Laboratories Inc.
To Be Announced Richard Mayeux, M.D.
The Biology of Depression and Dementia Gary W. Small, M.D.
Vascular Depression and Vascular Dementia K.R. Krishnan, M.D.
Mild Cognitive Impairment and Conversion to Alzheimer's Disease Davangere P. Devanand, M.D.
The Course of Treatment of Patients With Depression and Mild Cognitive Impairment Roy H. Hamilton, M.D.
9 a.m.-4 p.m.
CME Courses 20-25
1 p.m.-5 p.m.
CME Courses 26-32
1:30 p.m.-4:30 p.m.
Industry-Supported Symposia
IS13. Planning for Success in Schizophrenia Management Supported by Janssen Pharmaceutica and Research Foundation
Why Do Patients With Schizophrenia Take Their Medication? Adherence Models for First-Episode Patients Peter J. Weiden, M.D.
Schizophrenia Treatment Planning: Guidelines, Medication Algorithms, Psychosocial Strategies Dawn I. Velligan, Ph.D.
Strategies for Assessing and Managing Adherence Dilip V. Jeste, M.D.
IS14. Making Every Sheep Count: Evidence-Based Approaches to Treating Insomnia Supported by Takeda Pharmaceuticals North America Inc.
The Clinical Neuroscience of Sleep and Insomnia Daniel J. Buysse, M.D.
Comorbidity Between Insomnia and Psychiatric Illness Meera Narasimhan, M.D.
Novel Pharmacological Targets for the Management of Insomnia Ruth M. Benca, M.D.
Innovative Behavioral Approaches for Treating Insomnia and Comorbid Psychiatric Illness Karl Doghramji, M.D.
IS15. Rethinking Bipolar Disorder: Implications of Comorbidities Supported by AstraZeneca Pharmaceuticals
Medical Comorbidities With Bipolar Disorder Gary S. Sachs, M.D.
Comorbid Substance Abuse in Bipolar Disorder Michael J. Ostacher, M.D.
Suicidality as a Component of Bipolar Disorder Lauren Marangell, M.D.
Posttraumatic Stress Disorder and Bipolar Disorder: Critical Overlaps and Possible Links in Pathology and Treatment Lori L. Davis, M.D.
Neuroimaging of Dual Diagnoses Stephen M. Strakowski, M.D.
IS16. Caring for Our Most Challenging Patients With Depression: An Interactive Forum on Novel Treatments Supported by Cyberonics Inc.
Mechanism of Action of Vagus Nerve Stimulation Charles B. Nemeroff, M.D.
Efficacy of Repetitive Transcranial Magnetic Stimulation and Magnetic Seizure Therapy Thomas Schlaepfer, M.D.
Assessing the Efficacy of Vagus Nerve Stimulation in Patients With Treatment Resistant Depression James M. Martinez, M.D.
Mechanism of Action and Efficacy of Deep Brain Stimulation Helen Mayberg, M.D.
2:30 p.m.-4 p.m.
Lecture
L1. Carl P. Malmquist, M.D., AAPL/APA's Manfred S. Guttmacher Award Lecture
7 p.m.-10 p.m.
Industry-Supported Symposia
IS17. How Comorbid Is ADHD? Results From Epidemiological and Clinical Studies Supported by Shire U.S. Inc.
Patterns of Comorbidity in a Longitudinal Sample of Boys and Girls With ADHD Joseph Biederman, M.D.
Patterns of Comorbidity in a Clinical Sample of Adults With ADHD Thomas J. Spencer, M.D.
Patterns of Comorbidity in a Community Sample of Adults With ADHD: Results From the National Comorbidity Survey Ronald C. Kessler, Ph.D.
Morphometric Findings in Adults With ADHD With and Without Comorbid Bipolar Disorder Mike Monuteaux, Sc.D.
Spectroscopic Findings in Children and Comorbid Bipolar Disorder Perry F. Renshaw, M.D.
IS18. The Alcohol-Dependent Patient: Improving Outcomes Through Adherence Supported by Cephalon Inc.
Patient Adherence in the Treatment of Alcohol Dependence: Improving the Journey Toward Abstinence Helen Pettinati, Ph.D.
Selecting Pharmacotherapies to Improve Patient Adherence Robert M. Swift, M.D., Ph.D.
To Be Announced Carlo DiClemente, Ph.D.
Implementing Adherence-Enhancing Strategies in Clinical Practice With Alcohol-Dependent Patients Shimi Kang, M.D.
IS19. Weighing the Risks and Benefits of Atypical Antipsychotics: Can We Have Our Cake and Eat It Too? Supported by Bristol-Myers Squibb Co.
High Morbidity and Mortality in Schizophrenia and Bipolar Disorder: What, Why, and How? Quinton E. Moss, M.D.
Metabolic Complications in the Context of Antipsychotic Effectiveness: Lessons From the CATIE Schizophrenia Trial Donald C. Goff, M.D.
The Dual Health Jeopardy in Schizophrenia: Highly Prevalent Metabolic Disorders and Low Access to Medical Treatment Henry A. Nasrallah, M.D.
Managing Metabolic Complications During Antipsychotic Therapy: Lessons From ATP III, the ADA, and the APA Workgroup on Antipsychotics and Metabolic Risk John W. Newcomer, M.D.
Patient, Provider and System-Level Approaches to Reducing Risk of Poor Health Outcomes Lisa Dixon, M.D.
IS20. STAR*D Findings: Implications for Patients, Clinicians, and Other Stakeholders Supported by Forest Laboratories Inc.
Clinical Methods and Procedures to Enhance Acute and Long-Term Outcomes Junius J. Gonzales, M.D.
STAR*D: Selecting Among First- and Second-Step Acute Treatments Marlene P. Freeman, M.D.
STAR*D: Treatments After the First Two Steps, Including Follow-Up A. John Rush, M.D.
The Role of Other Treatment Options in Managing Depression K. Ranga Krishnan, M.D. ▪
Information & Authors
Information
Published In
History
Published online: 16 February 2007
Published in print: February 16, 2007
Authors
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
There are no citations for this item
View Options
View options
Get Access
Login options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).